These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 39236736

  • 1. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
    Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P.
    Lancet Gastroenterol Hepatol; 2024 Nov; 9(11):981-996. PubMed ID: 39236736
    [Abstract] [Full Text] [Related]

  • 2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group.
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [Abstract] [Full Text] [Related]

  • 3. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S, GARDENIA Study Group.
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
    [Abstract] [Full Text] [Related]

  • 4. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis.
    Nalagatla N, Falloon K, Tran G, Borren NZ, Avalos D, Luther J, Colizzo F, Garber J, Khalili H, Melia J, Bohm M, Ananthakrishnan AN.
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):502-509.e1. PubMed ID: 29944926
    [Abstract] [Full Text] [Related]

  • 5. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W, CONDUCT study group.
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [Abstract] [Full Text] [Related]

  • 6. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.
    Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, Mulcahy HE, Cullen G, Doherty GA.
    Clin Gastroenterol Hepatol; 2015 Feb; 13(2):330-335.e1. PubMed ID: 25086187
    [Abstract] [Full Text] [Related]

  • 7. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
    Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T, HAYABUSA Study Group.
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):429-437. PubMed ID: 33887262
    [Abstract] [Full Text] [Related]

  • 8. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.
    Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Lancet; 2012 Dec 01; 380(9857):1909-15. PubMed ID: 23063316
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J, HIBISCUS Study Group.
    Lancet Gastroenterol Hepatol; 2022 Jan 01; 7(1):17-27. PubMed ID: 34798036
    [Abstract] [Full Text] [Related]

  • 12. Use of Accelerated Induction Strategy of Infliximab for Ulcerative Colitis in Hospitalized Patients at a Tertiary Care Center.
    Govani SM, Berinstein JA, Waljee AK, Stidham RW, Higgins PDR, Hardiman KM.
    Dig Dis Sci; 2020 Jun 01; 65(6):1800-1805. PubMed ID: 31748921
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM, Faubion WA, Kugathasan S, Kierkus J, Ruemmele FM, Shimizu T, Mostafa NM, Venetucci M, Finney-Hayward T, Sanchez Gonzalez Y, Bereswill M, Lazar A, Turner D.
    Lancet Gastroenterol Hepatol; 2021 Aug 01; 6(8):616-627. PubMed ID: 34153231
    [Abstract] [Full Text] [Related]

  • 14. Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis.
    Seah D, Choy MC, Gorelik A, Connell WR, Sparrow MP, Van Langenberg D, Hebbard G, Moore G, De Cruz P.
    J Gastroenterol Hepatol; 2018 Jan 01; 33(1):226-231. PubMed ID: 28618062
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.
    Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A.
    Lancet Gastroenterol Hepatol; 2016 Sep 01; 1(1):15-24. PubMed ID: 27595142
    [Abstract] [Full Text] [Related]

  • 17. High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.
    Chao CY, Al Khoury A, Aruljothy A, Restellini S, Wyse J, Afif W, Bitton A, Lakatos PL, Bessissow T.
    Dig Dis Sci; 2019 Feb 01; 64(2):518-523. PubMed ID: 30446928
    [Abstract] [Full Text] [Related]

  • 18. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L.
    Lancet; 2021 Jun 19; 397(10292):2372-2384. PubMed ID: 34090625
    [Abstract] [Full Text] [Related]

  • 19. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT).
    Williams JG, Alam MF, Alrubaiy L, Clement C, Cohen D, Grey M, Hilton M, Hutchings HA, Longo M, Morgan JM, Rapport FL, Seagrove AC, Watkins A.
    Health Technol Assess; 2016 Jun 19; 20(44):1-320. PubMed ID: 27329657
    [Abstract] [Full Text] [Related]

  • 20. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baía C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S, BERGAMOT Study Group.
    Lancet Gastroenterol Hepatol; 2023 Jan 19; 8(1):43-55. PubMed ID: 36240801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.